Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 57.5%

Neg 0% Neu 57.5% Pos 0%

Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $100 price target.